

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Uri WORMSER

Confirmation No.: 2632

Application No.: 10/790,888

Patent No.: 7,238,656 B2

Filing Date: March 1, 2004

Patent Date: July 3, 2007

For: PROTECTIVE FACTORS AGAINST
INFLAMMATION, BURNS AND
NOXIOUS STIMULI

Attorney Docket No.: 85189-5800

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.322

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Patentees hereby respectfully request the issuance of a Certificate of Correction in connection with the above-identified patent. The corrections are listed on the attached Form PTO-1050. The corrections requested are as follows:

Column 26:

Line 66 (claim 1, line 24), after “(SEQ ID NO: 14)”, insert -- ; --.

Column 27:

Line 2 (claim 1, line 26), after “(SEQ ID NO: 11)”, insert -- ; --.

Line 35 (claim 11, line 1), after “A peptide”, delete “is”.

Column 28:

Line 16 (claim 11, line 17), after “(NO: 13)”, insert -- ; --.

Line 18 (claim 11, line 19), after “(NO: 10)”, insert -- ; --.

Line 20 (claim 11, line 21), after “(NO: 12)”, insert -- ; --.

Line 22 (claim 11, line 23), after “(SEQ ID NO: 14)”, insert -- ; --.

Line 24 (claim 11, line 25), after “(NO: 11)”, insert -- ; --.

Support for the above changes to claim 1 appear in application claim 10, and support for the changes to claim 11 appear in application claim 36.

The requested corrections are for errors that appear to have been made by the Office. Therefore, no fee is believed to be due for this request. Should any fees be required, however, please charge such fees to Winston & Strawn LLP Deposit Account No. 50-1814. Please issue a Certificate of Correction in due course.

Respectfully submitted,

7-19-07
Date


Allan A. Fanucci, Reg. No. 30,256

WINSTON & STRAWN LLP
Customer No. 28765

212-294-3311

-continued

<212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 10

Lys Gly Asn Tyr Ala Glu Arg Val Gly
 1 5

<210> SEQ ID NO 11
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 11

Lys Gly Asn Tyr Ser Glu Arg Val Gly
 1 5

<210> SEQ ID NO 12
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 12

Lys Ala His Tyr Ser Glu Arg Val Gly
 1 5

<210> SEQ ID NO 13
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 13

Lys Gly His Tyr Ala Glu Arg Val Gly
 1 5

<210> SEQ ID NO 14
 <211> LENGTH: 11
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 14

Lys Ser Arg Thr Thr Ser His Gly Arg Val Gly
 1 5 10

What is claimed is:

1. A pharmaceutical composition comprising as an active ingredient a peptide selected from the group consisting of:
 H-Lys-Gly-Asn-Tyr-Ala-Glu-Arg-Ileu-Ala-OH (SEQ ID

NO: 1);
 H-Asp-Thr-Glu-Phe-Glu-Ala-Ala-Gly-Gly-Gly-Val-Arg- 60
 OH (SEQ ID NO:2);

H-Thr-Thr-Asp-Thr-Glu-Phe-Glu-Ala-Ala-Gly-Gly-Gly-
 Val-Arg-OH (SEQ ID NO:4);

H-Lys-Gly-Asn-Tyr-MeAla-Glu-Arg-Ileu-Ala-OH (SEQ 65
 ID NO: 5);

H-Lys-Gly-Asn-Tyr-Ala-Glu-Arg-Melleu-Ala-OH (SEQ
 ID NO:6);

H-Lys-MeGly-Asn-Tyr-Ala-Glu-Arg-Ileu-Ala-OH (SEQ
 ID NO:7);

H-Lys-MeGly-Asn-Tyr-Ala-Glu-Arg-Melleu-Ala-OH
 (SEQ ID NO:8);

H-Lys-Gly-His-Tyr-Ala-Glu-Arg-Val-Gly-OH (SEQ ID
 NO: 13);

H-Lys-Gly-Asn-Tyr-Ala-Glu-Arg-Val-Gly-OH (SEQ ID
 NO: 10);

H-Lys-Ala-His-Tyr-Ser-Glu-Arg-Val-Gly-OH (SEQ ID
 NO: 12);

H-Lys-Ser-Arg-Thr-Thr-Ser-His-Gly-Arg-Val-Gly-OH
 (SEQ ID NO: 14);

27

- H-Lys-Gly-Asn-Tyr-Ser-Glu-Arg-Val-Gly-OH (SEQ ID NO: 1);
 H-Lys-MeGly-Asn-Tyr-MeAla-Glu-Arg-Melleu-Ala-OH (SEQ ID NO: 16); and
 their N-methylated analogs, together with a pharmaceutically acceptable diluent or excipient.
2. The pharmaceutical composition of claim 1, further comprising at least one protease inhibitor present in an amount sufficient to prevent peptide degradation.
3. The pharmaceutical composition of claim 1, further comprising at least one additional anti-inflammatory agent.
4. The pharmaceutical composition of claim 3, wherein the additional anti-inflammatory agent is a chemokine modulator.
5. A method for protecting an individual against thermal or chemical induced burns which comprises administering to an individual in need of such treatment a therapeutically effective amount of the pharmaceutical composition of claim 1.
6. The method of claim 5, wherein the pharmaceutical composition is administered prior to onset of thermal or chemical induced burns.
7. The method of claim 5, wherein the pharmaceutical composition is administered after onset of thermal or chemical induced burns.
8. The method of claim 5, wherein the pharmaceutical composition is administered by parenteral injection.
9. The method of claim 8, wherein the injection is selected from the group consisting of intravenous, intramuscular, intradermal, intralesional, intrathecal and subcutaneous injections.
10. The method of claim 5, wherein the pharmaceutical composition is administered via transdermal, oral, rectal, topical, nasal, inhalation or ocular modes of treatment.
11. A peptide selected from the group consisting of:

28

- H-Lys-Gly-Asn-Tyr-Ala-Glu-Arg-Ileu-Ala-OH (SEQ ID NO: 1);
 H-Asp-Thr-Glu-Phe-Glu-Ala-Ala-Gly-Gly-Gly-Val-Arg-OH (SEQ ID NO: 2);
 H-Thr-Thr-Asp-Thr-Glu-Phe-Glu-Ala-Ala-Gly-Gly-Val-Arg-OH (SEQ ID NO: 4);
 H-Lys-Gly-Asn-Tyr-MeAla-Glu-Arg-Ileu-Ala-OH (SEQ ID NO: 5);
 H-Lys-Gly-Asn-Tyr-Ala-Glu-Arg-Melleu-Ala-OH (SEQ ID NO: 6);
 H-Lys-MeGly-Asn-Tyr-Ala-Glu-Arg-Ileu-Ala-OH (SEQ ID NO: 7);
 H-Lys-MeGly-Asn-Tyr-Ala-Glu-Arg-Melleu-Ala-OH (SEQ ID NO: 8);
 H-Lys-Gly-His-Tyr-Ala-Glu-Arg-Val-Gly-OH (SEQ ID NO: 13);
 H-Lys-Gly-Asn-Tyr-Ala-Glu-Arg-Val-Gly-OH (SEQ ID NO: 10);
 H-Lys-Ala-His-Tyr-Ser-Glu-Arg-Val-Gly-OH (SEQ ID NO: 12);
 H-Lys-Ser-Arg-Thr-Thr-Ser-His-Gly-Arg-Val-Gly-OH (SEQ ID NO: 4);
 H-Lys-Gly-Asn-Tyr-Ser-Glu-Arg-Val-Gly-OH (SEQ ID NO: 11);
 H-Lys-MeGly-Asn-Tyr-MeAla-Glu-Arg-Melleu-Ala-OH (SEQ ID NO: 16); and
 a methylated analog thereof.
12. The peptide according to claim 11 consisting of the amino acid sequence H-Lys-Gly-Asn-Tyr-Ser-Glu-Arg-Val-Gly-OH (SEQ ID NO: 11).
13. The peptide according to claim 11 consisting of the amino acid sequence H-Lys-Gly-His-Tyr-Ala-Glu-Arg-Val-Gly-OH (SEQ ID NO: 13).

* * * *

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

PATENT NO.: 7,238,656 B2
APPLICATION NO.: 10/790,888
DATED: July 3, 2007
INVENTOR(S): Wormser

Page 1 of 1

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 26:

Line 66 (claim 1, line 24), after "(SEQ ID NO: 14)", insert -- ; --.

Column 27:

Line 2 (claim 1, line 26), after "(SEQ ID NO: 11)", insert -- ; --.

Line 35 (claim 11, line 1), after "A peptide", delete "is".

Column 28:

Line 16 (claim 11, line 17), after "(NO: 13)", insert -- ; --.

Line 18 (claim 11, line 19), after "(NO: 10)", insert -- ; --.

Line 20 (claim 11, line 21), after "(NO: 12)", insert -- ; --.

Line 22 (claim 11, line 23), after "(SEQ ID NO: 14)", insert -- ; --.

Line 24 (claim 11, line 25), after "(NO: 11)", insert -- ; --.